Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track JANX with free AI briefings, catalyst countdowns, and dilution alerts.

JANX · Janux Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$945.7M Cash on Hand
446.9mo Cash Runway
Follow JANX by email Get an email when JANX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about JANX, unsubscribe in one click. Privacy

📣 What JANX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Anti-PSMA/CD3 Protease-activated T-cell Engager… Prostate Cancer Phase 1 · NCT07813637 Recruiting
Anti-EGFR/anti-CD3 Tumor Protease-activated… Non-Small Cell Lung Cancer Phase 1 · NCT05783622 Active not recruiting
JANX013 Prostate Cancer Phase 1 · NCT07813637 Recruiting
Anti-PSMA/Anti-CD3 Dual-masked T-cell Engager… Prostate Cancer Phase 1 · NCT07545811 Recruiting
JANX011 Autoimmune Early Phase 1 · NCT07291323 Recruiting

Also used in these trials (approved or third-party drugs, not JANX's own candidates): Darolutamide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

JANX holds $945.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $6.3M/quarter from operations, an estimated runway of 446.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when JANX files for a raise →

👥 Who Owns JANX

Insiders 3.5% Institutions (290 holders) 96.5% Public and other holders 0%
HolderTypeShares% of sharesAs of
BlackRock, Inc. Institution (13G, 5%+) 4,098,457 6.70% 2026-06-30
W. Lawrence Hawkins Institution (13G, 5%+) 3,150,450 5.15% 2026-11-10
RA CAPITAL MANAGEMENT, L.P.
Director, 10% owner · +27,167 options
Insider 1,048,406 1.71% 2026-06-11
David Alan Campbell
President and CEO, Director · +1.04M options
Insider 264,742 0.43% 2026-07-31
Thomas DiRaimondo
Chief Scientific Officer · +109,900 options
Insider 155,825 0.25% 2026-01-02
Sheila Gujrathi
Director · +11,667 options
Insider 118,889 0.19% 2025-06-11
Charles M. Winter
Chief Technical Officer · +100,100 options
Insider 106,321 0.17% 2026-01-02
Andrew Hollman Meyer
Chief Business Officer · +192,101 options
Insider 83,095 0.14% 2026-01-02
Vickie L Capps
Director · +27,167 options
Insider 79,598 0.13% 2026-06-11
Janeen Noel Doyle
Chief Corp. & Bus. Dev. Ofcr · +280,000 options
Insider 75,941 0.12% 2026-06-02
Zachariah McIver
Chief Medical Officer · +101,500 options
Insider 52,286 0.09% 2026-01-02
William Go
Chief Medical Officer · +154,000 options
Insider 44,000 0.07% 2026-02-02

Share count 61,183,417 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full JANX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for JANX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.